中国经济网北京12月16日讯 金迪克(688670.SH)今日股价下跌，收报22.26元，跌幅7.02%。 金迪克于2021年8月2日在上交所科创板上市，公开发行新股2200万股，发行价格55.18元/股，保荐机构 为中信证券，保荐代表人为周游、赵岩。该股目前处于破发状态。 金迪克首次公开发行股票募集资金总额为12.14亿元，募集资金净额11.36亿元，较原拟募资净额少4.64 亿元。金迪克此前披露的招股书显示，该公司原拟募资16亿元，分别用于新建新型四价流感病毒裂解疫 苗车间建设项目、创新疫苗研发项目、补充流动资金及偿还银行借款项目。 金迪克首次公开发行股票的发行费用合计7828.39万元，其中，承销费及保荐费6433.99万元。中信证券 的子公司中信证券投资有限公司跟投比例为4%，获配股份数量为88.00万股，获配金额4855.84万元，限 售期限为24个月。 2023年5月19日，金迪克发布2022年年度权益分派实施公告。本次利润分配及转增股本以方案实施前的 公司总股本88,000,000股为基数，每股派发现金红利0.2元（含税），以资本公积金向全体股东每股转增 0.4股，共计派发现金红利17,600, ...

Core Insights - The company JinDike (688670.SH) reported a revenue of 3.524 million yuan for the first half of 2025, representing a year-on-year increase of 7.18% [1][2] - The net profit attributable to the parent company was -39.653 million yuan, with a net profit excluding non-recurring items of -42.941 million yuan [1][2] - The net cash flow from operating activities was -85.488 million yuan [1][2] Financial Performance - For the first half of 2025, the company achieved a revenue of 3,524,238.84 yuan, up from 3,288,169.37 yuan in the same period last year, marking a 7.18% increase [2] - The net profit attributable to shareholders was -39,653,098.13 yuan, slightly improved from -40,867,089.23 yuan year-on-year [2] - The net profit after excluding non-recurring items was -42,940,823.45 yuan, compared to -47,145,812.18 yuan in the previous year [2] - The net cash flow from operating activities was -85,488,113.52 yuan, an improvement from -89,270,106.59 yuan in the same period last year [2] Yearly Comparison - In 2024, the company reported a revenue of 80.802 million yuan, a significant decrease of 39.96% compared to 134.591 million yuan in 2023 [3] - The net profit attributable to shareholders for 2024 was -93.502 million yuan, worsening from -70.990 million yuan in 2023 [3] - The net profit excluding non-recurring items was -106.224 million yuan, compared to -72.571 million yuan in the previous year [3] IPO and Fundraising - JinDike raised a total of 1.214 billion yuan from its initial public offering, with a net amount of 1.136 billion yuan, which was 464 million yuan less than initially planned [4] - The funds were intended for the construction of a new vaccine production facility, vaccine research and development, working capital, and repayment of bank loans [4] - The underwriting fees for the IPO totaled 78.2839 million yuan, with CITIC Securities receiving 64.3399 million yuan [4]

Financial Performance - In 2024, the company reported operating revenue of 80.80 million yuan, a year-on-year decrease of 39.96% [1] - The net profit attributable to shareholders was -93.50 million yuan, compared to -70.99 million yuan in the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -106 million yuan, down from -72.57 million yuan year-on-year [1] - The net cash flow from operating activities was -131 million yuan, compared to 80.90 million yuan in the previous year [1] - For Q1 2025, the company achieved operating revenue of 3.46 million yuan, a decrease of 30.97% year-on-year [1] - The net profit attributable to shareholders for Q1 2025 was -17.58 million yuan, compared to -21.49 million yuan in the same period last year [1] - The net cash flow from operating activities for Q1 2025 was -42.06 million yuan, compared to -45.35 million yuan in the previous year [1] Dividend Policy - The company plans not to distribute profits for the 2024 fiscal year, with no cash dividends, capital reserve transfers, or stock bonuses [1] IPO and Fundraising - The company was listed on the Sci-Tech Innovation Board on August 2, 2021, with an initial public offering of 22 million shares at a price of 55.18 yuan per share [2] - The total amount raised from the IPO was 1.214 billion yuan, with a net amount of 1.136 billion yuan, which was 464 million yuan less than the originally planned net amount [2] - The company initially aimed to raise 1.6 billion yuan for various projects, including the construction of a new vaccine production facility and research and development [2] - The total issuance costs for the IPO were 78.28 million yuan, with the underwriter, CITIC Securities, receiving 64.34 million yuan in fees [2]